Stay updated on Clinical Trial: INO-3112 & Durvalumab for HPV Cancers

Sign up to get notified when there's something new on the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page.
Latest website image capture
Clouds background image

Latest updates to the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.4 instead of v3.5.3, indicating a recent software revision. This update does not modify any study details or displayed content.
    Difference
    0.0%
    Check dated 2026-05-15T14:19:06.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    Updates the platform’s displayed revision number from v3.5.2 to v3.5.3 for the study details view.
    Difference
    0.0%
    Check dated 2026-04-24T05:56:37.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:12:43.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Difference
    0.0%
    Check dated 2026-03-19T00:15:20.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 of the page template. The update is a back-end/template change and does not modify study data or visible content.
    Difference
    0.0%
    Check dated 2026-03-11T17:58:26.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    The updates look like a layout/content reorganization of the study page. No trial data, eligibility criteria, or outcomes appear to have changed.
    Difference
    0.0%
    Check dated 2026-03-04T13:52:53.000Z thumbnail image

Stay in the know with updates to Clinical Trial: INO-3112 & Durvalumab for HPV Cancers

Enter your email address, and we'll notify you when there's something new on the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page.